# of Displayed Technologies: 40 / 41

Applied Category Filter (Click To Remove): Small Molecules


Categories

Small Molecule USP30 Inhibitors for the Treatment and Prevention of Cardiomyopathy
TS-066773 — The Need Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…
  • College: College of Medicine (COM)
  • Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
  • Licensing Officer: Willson, Christopher

Innovative Small Molecule Inhibitors for Effective Treatment and Prevention of Coronavirus Infections
TS-066750 — The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health and economies. Despite vaccine efforts, issues such as vaccine hesitancy, delays in distribution, and emerging variants have highlighted the need for effective therapeutic interventions. These i…
  • College: College of Veterinary Medicine
  • Inventors: Sharma, Amit; Li, Pui-Kai "Tom"; Xing, Enming
  • Licensing Officer: Dahlman, Jason "Jay"

Method for sensitizing solid tumors to immunotherapy
TS-065862 — The Need In the landscape of cancer treatment, the emergence of immunotherapy has shown remarkable promise. However, its efficacy is not universal across all cancer types, and resistance development poses a significant challenge. Hyperprogression, characterized by accelerated tumor growth, further …
  • College: College of Arts & Sciences
  • Inventors: Kural, Comert; Djakbarova, Umidahan
  • Licensing Officer: Wilburn, Adri

Targeted Delivery to Cancer Cells using Self-assembled, Camptothecin Nanotubes: Active and Passive Targeting
TS-065860 — The Need: Cancer remains one of the most pressing medical challenges of our time, demanding innovative solutions to enhance treatment efficacy while minimizing systemic toxicity. Conventional chemotherapy agents often suffer from poor solubility, instability, and indiscriminate cytotoxicity, necessi…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Magliery, Thomas
  • Licensing Officer: Willson, Christopher

Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
  • College: College of Medicine (COM)
  • Inventors: Kerur, Nagaraj
  • Licensing Officer: Schultz, Teri

Precision RNA-PROTACs: Revolutionizing Therapeutic Targeting of Dysregulated Ribonucleoprotein Complexes
TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…
  • College: College of Arts & Sciences
  • Inventors: Bong, Dennis; Liang, Yufeng; Miao, Shiqin "Shiqin"; Strong, Rebekah
  • Licensing Officer: Willson, Christopher

Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells. The Need Current therapies…
  • College: College of Medicine (COM)
  • Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
  • Licensing Officer: Schultz, Teri

Utilizing WT-IV-012 to improve immune checkpoint therapy in cancer treatment
TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…
  • College: College of Arts & Sciences
  • Inventors: Burd, Craig; Aguilar-Valenzuela, Renan; Burd, Christin
  • Licensing Officer: Willson, Christopher

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

Small molecules that suppress heat/pain perception
TS-064187 — The Need In the culinary and pharmaceutical realms, the need for a groundbreaking solution to modulate flavor and alleviate sensory perceptions is crucial. Businesses seek innovative ways to enhance consumer experiences by addressing pungency in foods and alleviating burn or pain sensations in phar…
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Peterson, Devin; borcherding, Joel
  • Licensing Officer: Dahlman, Jason "Jay"

Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings. The Need The rise of these resilient multi-drug resistant bacteria has …
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Schultz, Teri

Protecting the vascular endothelial barrier – a novel approach to treating atrial fibrillation
TS-063433 — A new pharmacologic modality for treating AFib.
Atrial fibrillation (AF) is the most common form of irregular cardiac rhythm (arrhythmia), affecting approximately 3% of the US population. It is a significant risk factor for heart failure, ischemic stroke, and sudden cardiac death. The AF mortality rate is growing globally, and risk factors known …
  • College: College of Engineering (COE)
  • Inventors: Veeraraghavan, Rengasayee; Mezache, Louisa
  • Licensing Officer: Schultz, Teri

Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: OSU Wexner Medical Center
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: College of Pharmacy
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
  • Licensing Officer: Schworer, Adam

Addressing the Treatment Gap in Advanced Liposarcoma
TS-062480 — Novel therapeutic compounds to treat advanced liposarcoma.
Patients diagnosed with advanced liposarcoma (LPS) face a significant treatment challenge, as current chemotherapy approaches exhibit low response rates of only 25%, leading to a dismal overall survival at 5 years, ranging between 20% to 34%. The Need Despite extensive efforts, there has been no s…
  • College: College of Medicine (COM)
  • Inventors: Beane, Joal; Goryunova, Marina; Hadad, Christopher; He, Yiran; Zhu, Hua
  • Licensing Officer: Schultz, Teri

Novel use of novobiocin to potentiate the antimicrobial efficacy of polymyxins
TS-062439 — The Need: Addressing the Growing Threat of Gram-Negative Bacterial Infections Gram-negative bacterial pathogens, including Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae, are responsible for more than 35% of common hospital-acquired infections. These no…
  • College: College of Arts & Sciences
  • Inventors: Kahne, Daniel; Baidin, Vadim; Mandler, Michael; Ruiz, Natividad
  • Licensing Officer: Dahlman, Jason "Jay"

Unleashing the Power of Radiotherapy - Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.
Papaverine is an FDA-approved phosphodiesterase 10A (PDE10A) inhibitor and its clinical use is due to these effects on blood pressure and vascular tone. However, it was found to also be a potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been sho…
  • College: College of Medicine (COM)
  • Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
  • Licensing Officer: Schultz, Teri

FraB as a drug target and FraB inhibitors as Salmonella-specific narrow-spectrum therapeutics
TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics of salmonellosis, as well as small molecule inhibitors of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy of FraB inhibitors.
Non-typhoidal salmonellosis is one of the most significant food-borne diseases, in the United States and globally. There are no vaccines available for human use to prevent this disease, and only broad-spectrum antibiotics available to treat the disease. However, antibiotic resistance is on the ris…
  • College: College of Medicine (COM)
  • Inventors: Ahmer, Brian; Boulanger, Erin; Cool, Austin; Gopalan, Venkat; Kovvali, Sai Sravya Varali; Law, Jamison; Lindert, Steffen; Sabag-Daigle, Anice; Sengupta, Anindita; Thirugnanasambantham, Pankajavalli
  • Licensing Officer: Schultz, Teri

An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
  • College: College of Medicine (COM)
  • Inventors: Bansal, Shyam; Gumina, Richard
  • Licensing Officer: He, Panqing

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
  • College: College of Pharmacy
  • Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
  • Licensing Officer: He, Panqing

Inhibition of DGAT for the treatment of cancer
TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…
  • College: College of Medicine (COM)
  • Inventors: Guo, Deliang
  • Licensing Officer: He, Panqing

Novel epipolythiodioxopiperazine alkaloid natural product derivatives for the treatment of cancer and other diseases
TS-047118 — Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: He, Panqing

Electrophiles for Re-activation of Aged Acetylcholine Esterase
TS-044619 — Organophosphorus (OP) poisons including sarin, VX, and novichoks are lethal agents of chemical warfare. Their toxicity is due to their direct inhibition of acetylcholinesterase (AChE), an enzyme that is vital to the nervous system via regulation of the neurotransmitter acetylcholine (ACh). AChE in…
  • College: College of Arts & Sciences
  • Inventors: Hadad, Christopher; Callam, Christopher; Corrigan, Thomas; Dicken, Rachel; Dogan Ekici, Ozlem; Fitzpatrick, Keegan; Franjesevic, Andrew; McElroy, Craig; McKenney, Ryan; Muthukrishnan, Siva; Sanan, Toby; Vyas, Shubham; Yoder, Ryan; Young, Amneh "Amneh"
  • Licensing Officer: Willson, Christopher

Translational Activators of the Glutamate Transporter EAAT2 to Treat Neurological and Psychiatric Diseases
TS-043938 — Small molecule technology with novel translational activation mechanism.
Glutamate is a major neurotransmitter in the mammalian central nervous system (CNS) and essential for normal brain function including cognition, memory, and learning. However, the extracellular concentration of glutamate must remain below excitotoxic levels (~ 1 μM) to avoid overstimulation of …
  • College: College of Medicine (COM)
  • Inventors: Lin, Chien-Liang
  • Licensing Officer: Schworer, Adam

AR-12 for the Treatment of Leishmaniasis (Protozoa)
TS-041764 — AR-12 is a FDA-IND approved small molecule that has been repurposed to treat leishmaniasis, a parasitic infection.
Leishmaniasis is a protozoal parasitic disease transmitted by sandflies. The disease affects millions of people worldwide. Sandflies carrying the promastigote form of the parasite bite a human host, attracting macrophages to the site of the wound. Promastigotes are then phagocytized by the macroph…
  • College: College of Medicine (COM)
  • Inventors: Satoskar, Abhay; Ainslie, Kristy; Bachelder, Eric; Gautam, Shalini; Peine, Kevin
  • Licensing Officer: Schultz, Teri

A Small Molecule That Disperses Salmonella Biofilms
TS-041469 — A new compound to eliminate Salmonella biofilms to reduce typhoid fever.
The bacterium Salmonella enterica serovar Typhi (S. Typhi) is the causative agent of typhoid fever – infecting and killing an estimated 21 million and 200,000 individuals each year, respectively. Individuals contract the disease by consuming food or water contaminated with the etiologic agent …
  • College: College of Medicine (COM)
  • Inventors: Gunn, John; Huggins, William; Kuo, Laura; Melander, Christian
  • Licensing Officer: Taysavang, Panya

Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: He, Panqing

Targeted molecules for the treatment of cancer
TS-038027 — Novel dihdroorotate dehydrogenase (DHODH) small-molecule inhibitors for the treatment of Acute Myeloid Leukemia, Multiple Myeloma, & Graft vs. Host Disease / Leukemia.
DHODH is a rate-limiting enzyme in de novo pyrimidine synthesis. Rapidly dividing cancer cells are therefore sensitive to blockade of this pathway. New research has shown DHODH inhibition can induce differentiation in acute myeloid leukemia (AML) cell lines, translating to increased survival in an…
  • College: College of Medicine (COM)
  • Inventors: Byrd, John; Abdulrahim, Mouad; Elgamal, Ola; Goodwin, Thomas; Hertlein, Erin; Ravikumar, Pratheepa; Shah, Dimple
  • Licensing Officer: Schworer, Adam

Oral cancer chemopreventive rinse
TS-037788 — Rinses with sustained contact time and field coverage have been developed to prevent oral cancer.
Oral cancer affects nearly 50,000 Americans each year and has a five year survival rate of 57%. Often, oral cancer is only discovered when it has metastasized, as it does not present recognizable symptoms, and it has a high risk of producing secondary tumors. Oral squamous cell carcinoma (OSCC), a…
  • College: College of Dentistry
  • Inventors: Mallery, Susan; Lahann, Joerg
  • Licensing Officer: Schultz, Teri

Novel peptides for the treatment of type 1 and 2 diabetes and their neurological complications
TS-037747 — A novel peptide therapeutic AAC2 comprising amino acids with a coumarin-modified side chain that improves glucose control and reduces neurological decline and anxiety through activation of the insulin-insensitive glucose transporter 1 (GLUT1).
A national study done in 2016 on US adults with diabetes estimated that 0.5% of the population was diagnosed with type 1 diabetes (T1D) (~1.6 million) and 8.5% was diagnosed with type 2 diabetes (T2D) (~27 million). Globally there are ~415 million adults living with diabetes in 2015, with a projec…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: He, Panqing

Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
  • Licensing Officer: Taysavang, Panya

Novel Therapeutic for Influenza-Induced Acute Respiratory Distress Syndrome
TS-032198 — A parenteral administration of a naturally occurring chemical used to treat influenza­-induced hypoxemia, lung dysfunction, and acute respiratory distress syndrome (ARDS). This treatment could also be potentially useful in treating ARDS from other causes.
Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by impaired alveolar gas exchange, a symptom that leads to a lack of oxygen in the bloodstream. This lack of oxygen to vital organs can lead to organ failure and results in a high possibility of patient death. The infl…
  • College: College of Veterinary Medicine
  • Inventors: Davis, Ian
  • Licensing Officer: Dahlman, Jason "Jay"

Method to Synthesize Ceratamine A and B and Analogs Thereof
TS-030264 — A chemical process to produce ceratamine A and B.
The natural products ceratamines A and B were isolated from a marine sponge in minute quantities and shown to have potent anti-tumor activity. Due to the insufficient sample size and subsequent lack of availability of the producing sponge, evaluation was incomplete. Thus, the clinical potential ne…
  • College: College of Arts & Sciences
  • Inventors: Coleman, Robert "Rob"; Campbell, Erica
  • Licensing Officer: Panic, Ana

Estrogen Receptor Beta Agonist Compounds
TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.
There is a large emphasis on the need for novel and more effective cancer therapeutics, since there were nearly 600,000 cancer deaths in the United States in 2016 alone. One method for therapy of prostate, breast, and colon cancer that has been gaining traction is the targeting of estrogen recepto…
  • College: College of Pharmacy
  • Inventors: Tjarks, Werner; Bartunek, Petr; Sedlak, David
  • Licensing Officer: Taysavang, Panya

Small Molecule AR-Ablative Agents
TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.
Hormone-refractory prostate cancer is incurable, and patients with this disease have few treatment options. Dysregulation of the androgen receptor (AR) is a hallmark of this incurable cancer. Molecular changes during cancer enhance AR sensitivity or permit AR activation by antiestrogen so that pro…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Wang, Dasheng; Yang, Jian
  • Licensing Officer: Taysavang, Panya

Topical Compounds to Treat Leishmania
TS-014819 — A new class of drugs for the treatment of Leishmania.
Leishmaniasis is an infection caused by Leishmania parasites, spread by the bite of phlebotomine sand flies. It is prevalent in the tropics, subtropics, and southern Europe and is considered a neglected disease. Over a million people are infected with the parasite yearly, leading to skin sores and i…
  • College: College of Medicine (COM)
  • Inventors: Satoskar, Abhay; Fuchs, James; Isaac-Marquez, Angelica; Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Lezama-Davila, Claudio; Pan, Li
  • Licensing Officer: Schultz, Teri

Novel Indole-3-Carbinol-Derived Antitumor Agents
TS-014815 — An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.
According to the Center for Disease Control and Prevention, cancer is the second leading cause of death in the US at approximately 600,000 deaths per year. In addition, the National Cancer Institute estimates that nearly 1.7 million cases of cancer are diagnosed each year. A report from U.S. News …
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Weng, Jing-ru
  • Licensing Officer: Taysavang, Panya

Novel Protein Kinase C Delta Activators
TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.
The third leading cause of cancer death worldwide is hepatocellular carcinoma (HCC). Due to the rise in the incidence of hepatitis C virus infection, HCC is expected to increase in the United States. Many patients with HCC are not candidates for surgery because of the location or size of their tum…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Byrd, John; Kulp, Samuel; Muthusamy, Natarajan; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Show More Technologies

Loading icon